Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.
It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.
Clinical trials ongoing at the Institute:
- UCB MG0003 : A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis
- UCB MG0004 : A randomized, open-label extension study to investigate the long-term safety, tolerability of rozanolixizumab in adult patients with generalized myasthenia gravis
- UCB MG0007 : A Phase 3, open-label extension (OLE) study to evaluate 6-week treatment cycles of rozanolixizumab in study participants with gMG
- R3918-MG-2018 : Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
- MOM-M281-011 : Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis
Acronym |
UCB MG0003 |
UCB MG0004 |
UCB MG0007 |
| Intervention | rozanolixizumab | rozanolixizumab | rozanolixizumab |
| Principal investigator |
Sophie Demeret | Sophie Demeret | Sophie Démette |
| Sponsor | UCB | UCB | UCB |
| Study status | Ongoing | Ongoing | Ongoing |
| Recruitment status | Ongoing | Stopped | Completed |
| Population | Adult | Adult | Adul |
| + infos sur clinical trials.gov | + infos sur clinical trials.gov |
Acronym |
R3918-MG-2018 |
MOM-M281-011 |
| Intervention | pozelimab et cemdisiran | nipocalimab |
| Principal investigator | Sophie Demeret | Sophie Demeret |
| Sponsor | Regeneron | Jannsen-Cilag |
| Study status | In preparation | Ongoing |
| Recruitment status | In preparation | In preparation |
| Population | Adult | Adult |
Contact : essais-adultes@institut-myologie.org
